FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody or its antigen-binding fragment, which specifically bind to interleukin 17A (IL-17A), as well as to a composition containing it. Also disclosed is a nucleic acid molecule coding said antibody or its fragment, as well as a cell and a vector containing same.
EFFECT: invention is effective for treating or preventing diseases or disorders mediated by IL-17A.
15 cl, 13 dwg, 6 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICINAL AGENT FOR TREATING SOLID TUMOURS | 2020 |
|
RU2825845C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| IL-5 BINDING MOLECULE, METHOD OF ITS PREPARATION AND ITS USE | 2021 |
|
RU2811518C1 |
| HETERODIMERIC BISPECIFIC ANTIBODY AGAINST TNFα/AGAINST IL-17A, SIMILAR BY STRUCTURE TO NATURAL ANTIBODY, AND ITS PRODUCTION METHOD | 2019 |
|
RU2781816C1 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2014 |
|
RU2663795C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
